A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes.
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2009
At a glance
- Drugs CC 11006 (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 12 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Apr 2007 New trial record.